In vitro Susceptibility of Mycobacterium avium to a New Macrolide (RU-28965)
- 1 January 1987
- journal article
- research article
- Published by S. Karger AG in Chemotherapy
- Vol. 33 (4), 255-258
- https://doi.org/10.1159/000238504
Abstract
The in vitro susceptibility of Mycobacterium avium to RU-28965 alone and in combination with rifampin, isoniazid, and sulfametoxipiridazine was studied by the agar dilution method. The synergistic effect of the RU-28965 with rifampin has been demonstrated. At a concentration of 16 μg/ml or lower of RU-28965, 100% of M. avium strains were inhibited. If 2 μg/ml of rifampin is added the MIC of RU-28965 is lowered to 0.25 μg/ml.Keywords
This publication has 4 references indexed in Scilit:
- Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristicsJournal of Clinical Microbiology, 1985
- In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugsAntimicrobial Agents and Chemotherapy, 1983
- A drug sensitivity test strategy for atypical mycobacteriaTubercle, 1982
- INVITRO SUSCEPTIBILITY OF MYCOBACTERIUM-AVIUM COMPLEX AND MYCOBACTERIUM-TUBERCULOSIS STRAINS TO A SPIRO-PIPERIDYL RIFAMYCINPublished by Elsevier ,1982